Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2.
about
Epstein Barr virus/complement C3d receptor is an interferon alpha receptorMolecular interactions of complement receptors on B lymphocytes: a CR1/CR2 complex distinct from the CR2/CD19 complexIntersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B lymphocytesThe crystal structure of human CD21: Implications for Epstein-Barr virus and C3d binding.A crystal structure of the complex between human complement receptor 2 and its ligand C3dDetermination of the structural basis for selective binding of Epstein-Barr virus to human complement receptor type 2Sites within the complement C3b/C4b receptor important for the specificity of ligand binding.Laser-capture microdissection of oropharyngeal epithelium indicates restriction of Epstein-Barr virus receptor/CD21 mRNA to tonsil epithelial cells.Measles: immunosuppression, interleukin-12, and complement receptors.Recombinant complement receptor 2 radiolabeled with [99mTc(CO)3]+: a potential new radiopharmaceutical for imaging activated complementStructure and distribution of modules in extracellular proteins.Biophysical investigations of complement receptor 2 (CD21 and CR2)-ligand interactions reveal amino acid contacts unique to each receptor-ligand pairEpstein-Barr viruses that express a CD21 antibody provide evidence that gp350's functions extend beyond B-cell surface binding.Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation.Targeting pathogenic postischemic self-recognition by natural IgM to protect against posttransplantation cardiac reperfusion injuryVirus receptors: implications for pathogenesis and the design of antiviral agents.Complement receptor 1 (CR1) expression in chronic myeloid leukemia.Characterization of the echovirus 7 receptor: domains of CD55 critical for virus bindingMapping of the C3b-binding site of CR1 and construction of a (CR1)2-F(ab')2 chimeric complement inhibitor.Characterization of an Epstein-Barr virus receptor on human epithelial cells.Infection of human thymocytes by Epstein-Barr virus.Determination of the role for CD21 during Epstein-Barr virus infection of B-lymphoblastoid cells.Inhibition of Epstein-Barr virus infection in vitro and in vivo by soluble CR2 (CD21) containing two short consensus repeats.Regulation of humoral immunity by complement.Structure of the Epstein-Barr virus major envelope glycoprotein.Low cell dosage of lymphoblastoid human cell lines EBV(+) is associated to chronic hepatitis in a minority of inoculated Nu/Nu mice.Origin and properties of soluble CD21 (CR2) in human blood.Cross-linking of at least three binding sites mediates signal transduction in a CR2-positive Burkitt lymphoma derived cell line (Raji).Evidence for three binding sites for C3 (hemolytically inactive), C3b and C3d on a CR2-positive Burkitt lymphoma-derived cell line (Raji).Complement receptor type 2 mediates infection of the human CD4-negative Raji B-cell line with opsonized HIV.Isolating the Epstein-Barr virus gp350/220 binding site on complement receptor type 2 (CR2/CD21).Epstein-Barr virus receptors but not viral DNA are present in normal and malignant oral epithelium.Non-Invasive whole-body detection of complement activation using radionuclide imaging in a mouse model of myocardial ischaemia-reperfusion injury.The modular architecture of leukocyte cell-surface receptors.The requirement of localized, CR2-mediated, alternative pathway activation of complement for covalent deposition of C3 fragments on normal B cells.Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.
P2860
Q24561504-180B0803-7F70-4E1D-8D55-3E7313E23BF5Q24675919-A7A60E77-42AA-4F16-9793-49409F38ECC3Q24676040-FECBE9DB-24B3-4AB8-A9D1-33F7C3FEA8F7Q24680369-291EEB91-5B08-4285-AA05-04291657B8A5Q27639376-39143B0C-EAB0-4F4E-909C-EDD417EC3A51Q27667612-F67CAD68-4529-47A3-8AF3-4AAA91349400Q28756459-D6A7A0E9-F33A-4F0D-9748-136060EF4548Q30454140-70DAB463-4401-437B-AC1F-9EDB987765B4Q33360874-F939E528-FD4B-439C-8A0C-55A5BB17F8CBQ33683348-89263528-9013-4051-816E-0C9A0D8D271EQ33873704-107F8709-D6CB-4097-96E1-5872F96F3F71Q34063457-9DBE109B-3927-452B-818C-DED1A45C0CE4Q34094547-4F3E8B9A-8DDD-451F-90C8-C0AB8CF20972Q34613494-E4517734-2A8D-4B0E-9E8B-24A2D06B2193Q35095565-B9AD4322-685A-4ADB-94CD-C7AFEF724743Q35246399-076BD670-7FB2-4E1E-8049-01E98ADCF9F4Q35366667-374EF2C1-374B-4B4F-91E1-B483FB3714C5Q35664736-D4CAD562-C402-4EE5-BF69-5211F0D94098Q35845749-5C0D941B-452C-4EF5-8325-38ACAA7E7AF1Q36230727-C5742EBE-F81A-4852-B432-F10CA6293368Q36231943-DFD1F12F-030F-4311-90F5-41CEBBAF9CCDQ36360915-1110C8F7-4F91-415D-9BF3-1D1A9C4321CFQ36623632-A216E965-DE3E-4FEC-B35A-357D6CC9AFE4Q36700941-5E07CEF4-E013-4610-BBB4-5BAC58F3282FQ38037801-C82FE3FC-43D3-4E80-ACA4-2793280D59CFQ40214421-C3CB0E05-6A50-4DC8-8F03-28E277DA69B8Q40762511-7F2A5FC4-2E97-49D1-AD4C-DF8782307131Q41008970-A7E3AEED-93E8-4428-8909-0A80B499916BQ41294052-3614373F-9F89-439F-8D8F-71BB5A570B3DQ41547080-6FE10E88-211B-4DEE-870F-812450DF277CQ41593439-A0981996-9D61-4F4C-8BA5-7F762A7B8BE9Q45399777-0056F574-4BF0-4DCB-B8BC-4E0042912271Q45855383-D839649D-4E91-41A9-91DD-F19E4CE89336Q47115111-BAA76841-94C0-4A23-88C8-D0D2E9574CBFQ47700184-90D7D218-3D94-4C58-8892-4210A606C94CQ48003995-F7A8FFA8-AB73-408A-B679-AECE62F2E5E9Q54939538-D33065DD-52EA-45E9-AED5-3105C82A1E7D
P2860
Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Mapping of the Epstein-Barr vi ...... on complement receptor type 2.
@ast
Mapping of the Epstein-Barr vi ...... on complement receptor type 2.
@en
type
label
Mapping of the Epstein-Barr vi ...... on complement receptor type 2.
@ast
Mapping of the Epstein-Barr vi ...... on complement receptor type 2.
@en
prefLabel
Mapping of the Epstein-Barr vi ...... on complement receptor type 2.
@ast
Mapping of the Epstein-Barr vi ...... on complement receptor type 2.
@en
P2093
P2860
P356
P1476
Mapping of the Epstein-Barr vi ...... on complement receptor type 2.
@en
P2093
C A Lowell
D T Fearon
J A Mitchell
J M Ahearn
L B Klickstein
R H Carter
P2860
P304
P356
10.1084/JEM.170.6.1931
P407
P577
1989-12-01T00:00:00Z